204 related articles for article (PubMed ID: 28842319)
1. Quantitative phosphoproteomic analysis of acquired cancer drug resistance to pazopanib and dasatinib.
Vyse S; McCarthy F; Broncel M; Paul A; Wong JP; Bhamra A; Huang PH
J Proteomics; 2018 Jan; 170():130-140. PubMed ID: 28842319
[TBL] [Abstract][Full Text] [Related]
2. TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux.
D'Cunha R; Bae S; Murry DJ; An G
Biopharm Drug Dispos; 2016 Oct; 37(7):397-408. PubMed ID: 27418107
[TBL] [Abstract][Full Text] [Related]
3. Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib.
Gotink KJ; Rovithi M; de Haas RR; Honeywell RJ; Dekker H; Poel D; Azijli K; Peters GJ; Broxterman HJ; Verheul HM
Cell Oncol (Dordr); 2015 Apr; 38(2):119-29. PubMed ID: 25665527
[TBL] [Abstract][Full Text] [Related]
4. Preclinical impact of high dose intermittent antiangiogenic tyrosine kinase inhibitor pazopanib in intrinsically resistant tumor models.
Reguera-Nuñez E; Man S; Xu P; Kerbel RS
Angiogenesis; 2018 Nov; 21(4):793-804. PubMed ID: 29786782
[TBL] [Abstract][Full Text] [Related]
5. Activation of ERK1/2 Causes Pazopanib Resistance via Downregulation of DUSP6 in Synovial Sarcoma Cells.
Yokoyama N; Matsunobu T; Matsumoto Y; Fukushi JI; Endo M; Hatano M; Nabeshima A; Fukushima S; Okada S; Iwamoto Y
Sci Rep; 2017 Mar; 7():45332. PubMed ID: 28350009
[TBL] [Abstract][Full Text] [Related]
6. Whole-exome sequencing reveals potential mechanisms of drug resistance to FGFR3-TACC3 targeted therapy and subsequent drug selection: towards a personalized medicine.
Tong Z; Yan C; Dong YA; Yao M; Zhang H; Liu L; Zheng Y; Zhao P; Wang Y; Fang W; Zhang F; Jiang W
BMC Med Genomics; 2020 Sep; 13(1):138. PubMed ID: 32957974
[TBL] [Abstract][Full Text] [Related]
7. Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells.
Sesumi Y; Suda K; Mizuuchi H; Kobayashi Y; Sato K; Chiba M; Shimoji M; Tomizawa K; Takemoto T; Mitsudomi T
Lung Cancer; 2017 Feb; 104():85-90. PubMed ID: 28213007
[TBL] [Abstract][Full Text] [Related]
8. Dual Targeting of PDGFRα and FGFR1 Displays Synergistic Efficacy in Malignant Rhabdoid Tumors.
Wong JP; Todd JR; Finetti MA; McCarthy F; Broncel M; Vyse S; Luczynski MT; Crosier S; Ryall KA; Holmes K; Payne LS; Daley F; Wai P; Jenks A; Tanos B; Tan AC; Natrajan RC; Williamson D; Huang PH
Cell Rep; 2016 Oct; 17(5):1265-1275. PubMed ID: 27783942
[TBL] [Abstract][Full Text] [Related]
9. Phosphosignature predicts dasatinib response in non-small cell lung cancer.
Klammer M; Kaminski M; Zedler A; Oppermann F; Blencke S; Marx S; Müller S; Tebbe A; Godl K; Schaab C
Mol Cell Proteomics; 2012 Sep; 11(9):651-68. PubMed ID: 22617229
[TBL] [Abstract][Full Text] [Related]
10. Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors.
Hashida S; Yamamoto H; Shien K; Ohtsuka T; Suzawa K; Maki Y; Furukawa M; Soh J; Asano H; Tsukuda K; Miyoshi S; Kanazawa S; Toyooka S
Oncol Rep; 2015 Mar; 33(3):1499-504. PubMed ID: 25607753
[TBL] [Abstract][Full Text] [Related]
11. Cabozantinib and dastinib exert anti-tumor activity in alveolar soft part sarcoma.
Mukaihara K; Tanabe Y; Kubota D; Akaike K; Hayashi T; Mogushi K; Hosoya M; Sato S; Kobayashi E; Okubo T; Kim Y; Kohsaka S; Saito T; Kaneko K; Suehara Y
PLoS One; 2017; 12(9):e0185321. PubMed ID: 28945796
[TBL] [Abstract][Full Text] [Related]
12. The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo.
Booth L; Roberts JL; Sander C; Lee J; Kirkwood JM; Poklepovic A; Dent P
Oncotarget; 2017 Mar; 8(10):16367-16386. PubMed ID: 28146421
[TBL] [Abstract][Full Text] [Related]
13. Pazopanib, a novel multi-kinase inhibitor, shows potent antitumor activity in colon cancer through PUMA-mediated apoptosis.
Zhang L; Wang H; Li W; Zhong J; Yu R; Huang X; Wang H; Tan Z; Wang J; Zhang Y
Oncotarget; 2017 Jan; 8(2):3289-3303. PubMed ID: 27924057
[TBL] [Abstract][Full Text] [Related]
14. TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway.
Zizzari IG; Napoletano C; Botticelli A; Caponnetto S; Calabrò F; Gelibter A; Rughetti A; Ruscito I; Rahimi H; Rossi E; Schinzari G; Marchetti P; Nuti M
Cancer Immunol Res; 2018 Jun; 6(6):711-722. PubMed ID: 29700053
[TBL] [Abstract][Full Text] [Related]
15. A chemical and phosphoproteomic characterization of dasatinib action in lung cancer.
Li J; Rix U; Fang B; Bai Y; Edwards A; Colinge J; Bennett KL; Gao J; Song L; Eschrich S; Superti-Furga G; Koomen J; Haura EB
Nat Chem Biol; 2010 Apr; 6(4):291-9. PubMed ID: 20190765
[TBL] [Abstract][Full Text] [Related]
16. Anthelmintic drug niclosamide enhances the sensitivity of chronic myeloid leukemia cells to dasatinib through inhibiting Erk/Mnk1/eIF4E pathway.
Liu Z; Li Y; Lv C; Wang L; Song H
Biochem Biophys Res Commun; 2016 Sep; 478(2):893-9. PubMed ID: 27520370
[TBL] [Abstract][Full Text] [Related]
17. A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Wagle M; Eiring AM; Wongchenko M; Lu S; Guan Y; Wang Y; Lackner M; Amler L; Hampton G; Deininger MW; O'Hare T; Yan Y
Leukemia; 2016 Jul; 30(7):1493-501. PubMed ID: 27044711
[TBL] [Abstract][Full Text] [Related]
18. A new mechanism of resistance to ABL1 tyrosine kinase inhibitors in a BCR-ABL1-positive cell line.
Airiau K; Turcq B; Mahon FX; Belloc F
Leuk Res; 2017 Oct; 61():44-52. PubMed ID: 28888102
[TBL] [Abstract][Full Text] [Related]
19. High-Throughput Drug Screening Identifies Pazopanib and Clofilium Tosylate as Promising Treatments for Malignant Rhabdoid Tumors.
Chauvin C; Leruste A; Tauziede-Espariat A; Andrianteranagna M; Surdez D; Lescure A; Han ZY; Anthony E; Richer W; Baulande S; Bohec M; Zaidi S; Aynaud MM; Maillot L; Masliah-Planchon J; Cairo S; Roman-Roman S; Delattre O; Del Nery E; Bourdeaut F
Cell Rep; 2017 Nov; 21(7):1737-1745. PubMed ID: 29141209
[TBL] [Abstract][Full Text] [Related]
20. Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs.
Puvanenthiran S; Essapen S; Seddon AM; Modjtahedi H
Int J Oncol; 2016 Nov; 49(5):1825-1838. PubMed ID: 27599579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
